We recently published an article titled Market Slump Drags Down Share Prices of These 15 Companies. In this article, we are ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares were up 3.6% during mid-day trading on Thursday . The company ...

CapMetro recently shared several proposed updates on its website, including removing the CapMetro app ... like those part of ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt ... opinion intended to influence your ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the price target of $18.00. Discover top-rated stocks from ...

Highlights,Hims & Hers operates in the telehealth and wellness sector.,The company offers personalized solutions in ...

This scraper uses Playwright to complete the Hims weight loss medication intake form and record which medication the website recommends. Information entered into the form is drawn from a pre-defined ...

Morgan Stanley has recently initiated Hims & Hers Health Inc (HIMS) stock to Overweight rating, as announced on December 17, 2024, according to Finviz. Earlier, on November 14, 2024, BofA Securities ...

Top hair loss treatment providers, like Hims, use proprietary blends of Rx-quality ingredients that have undergone research studies and show promising results to help combat certain types of hair ...

Hims sells a compounded version of Novo Nordisk's (NVO) semaglutide, the active ingredient in Wegovy and Ozempic for, ...